Durata Therapeutics (DRTX) –
-
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
-
Biothera Pharmaceutical Inc. Announces Board of Directors
-
Durata Therapeutics (DRTX) Receives Positive CHMP Opinion on Xydalba as ABSSSI Treatment
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Canaan Management, Inc.
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Ahrens Brenton Karl
-
Form 4 Durata Therapeutics, For: Aug 26 Filed by: Canaan VIII LP
-
Form 4 Durata Therapeutics, For: Aug 26 Filed by: Ahrens Brenton Karl
-
Form SC 13D/A Durata Therapeutics, Filed by: Canaan VIII LP
-
Form SC 13D/A Durata Therapeutics, Filed by: AISLING CAPITAL III LP
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Giles Lisa M.
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: FRIEDMAN PAUL A
-
Form SC 13D/A Durata Therapeutics, Filed by: New Leaf Ventures II, L.P.
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: DE SCHUTTER RICHARD U
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: OBOYLE KEVIN C
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Fishman Corey N.
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: CARROLL J MARTIN
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: YARNO WENDY L
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Shannon John Patrick Jr
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Edick Paul R
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Dunne Michael W.
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Ratcliffe Liam
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Halak Brian K
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Halak Brian K
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: Kamdar Kim P.
-
Form 4 Durata Therapeutics, For: Nov 17 Filed by: VITULLO NICOLE
-
Form 8-K Durata Therapeutics, For: Nov 17
-
Form 8-K Durata Therapeutics, For: Nov 09
-
Form 10-Q Durata Therapeutics, For: Sep 30
-
Actavis (ACT), Durata Therapeutics (DRTX) Receive FTC Clearance for Acquisition
-
Roth Capital Downgrades Durata Therapeutics (DRTX) to Neutral
-
Credit Suisse Downgrades Durata Therapeutics (DRTX) to Neutral
-
Durata Therapeutics (DRTX) Presents New Data for DALVANCE
-
Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)
-
Form 8-K Durata Therapeutics, For: Oct 05
-
Actavis' (ACT) Move to Acquire Durata (DRTX) is Strategically Sound; Signals Appetite for More M&A - Moody's
-
RBC Capital Downgrades Durata Therapeutics (DRTX) to Sector Perform
-
Market Wrap: Becton Dickinson's Big Buy; Lights Out for GT Advanced Tech; Splitsville for H-P
-
Form 8-K Durata Therapeutics, For: Oct 05
-
Unusual 11 Mid-Day Movers 10/6: (DRTX) (UNIS) (CFN) Higher; (GTAT) (SNSS) (ADHD) Lower
-
Notable Mergers and Acquisitions of the Day 10/6: (BDX)/(CFN) (MBI) (ACT)/(DRTX) (CONN)
-
Pre-Open Stock Movers 10/06: (DRTX) (CFN) (CMRX) Higher; (SNSS) (ADHD) (HRB) Lower (more...)
-
Durata Therapeutics (DRTX) to Resume Trading at 8:30AM
-
Actavis (ACT) to Acquire Durata Therapeutics (DRTX) in $675M Deal
-
Durata Therapeutics (DRTX) halted with news pending
-
Unusual 11 Mid-Day Movers 10/3: (NXTD) (RMTI) (DRTX) Higher; (CLF) (XTLB) (CTCM) Lower
-
Pre-Open Stock Movers 10/03: (RSH) (SLXP) (MYL) Higher; (W) (CLF) (AAPL) Lower (more...)
-
Durata Therapeutics (DRTX) Receives FDA SPA for DALVANCE Phase 3
-
FDA Grants Durata Therapeutics a Special Protocol Agreement (SPA) for Its Phase 3 Study of DALVANCE(TM) in Hospitalized Community-Acquired Pneumonia
-
Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
-
Form 4 Durata Therapeutics, For: Aug 26 Filed by: CARROLL J MARTIN
Back to DRTX Stock Lookup